Skip to main content
OpenTrials

Clinical trial condition

Platinum-resistant Ovarian Cancer

Explore clinical trials studying Platinum-resistant Ovarian Cancer. Study availability and eligibility vary by location and protocol.

25 public trials 13 recruiting studies
Refine in advanced search Browse all conditions

Platinum-resistant Ovarian Cancer trial results

Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Cancer, +102 more
Locations
  • The Angeles Clinic and Research Institute Los Angeles, California, United States
  • START Midwest Grand Rapids, Michigan, United States
  • START-New York Long Island Lake Success, New York, United States
  • Providence Cancer Institute Portland, Oregon, United States
View Trial Details
Recruiting

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

NCT06315491

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +14 more
Locations
  • Honor Health Scottsdale, Arizona, United States
  • Arizona Oncology Associates Tucson, Arizona, United States
  • Usc Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
View all 17 locations
View Trial Details
Not Yet Recruiting

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

NCT07604766

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +15 more
Locations
  • Beijing Cancer Hospital Beijing, China
  • Peking Union Medical College Hospital Beijing, China
  • Chongqing University Cancer Hospital - Chongqing Cancer Hospital Chongqing, China
  • Fujian Provincial Cancer Hospital Fujian, China
View all 20 locations
View Trial Details
Completed

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

NCT05198804

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +18 more
Locations
  • Arizona Oncology Associates (Wilmot HOPE) - USOR Tucson, Arizona, United States
  • Rocky Mountain Cancer Centers Aurora, Colorado, United States
  • University of Colorado Aurora, Colorado, United States
  • Mount Sinai Comprehensive Cancer Center Miami Beach, Florida, United States
View all 22 locations
View Trial Details
Completed

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

NCT05483933

Conditions
Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +25 more
Locations
  • University of Arkansas for Medical sciences Little Rock, Arkansas, United States
  • City of Hope Duarte, California, United States
  • Robert H.Lurie ComprehensiveCancer Center, Northwestern University Chicago, Illinois, United States
  • START Midwest Grand Rapids, Michigan, United States
View all 21 locations
View Trial Details
Completed

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

NCT04374630

Conditions
Platinum-resistant Ovarian Cancer
Locations
  • Arizona Oncology Associates Phoenix, Arizona, United States
  • Arizona Oncology Tucson, Arizona, United States
  • Highlands Oncology Group Rogers, Arkansas, United States
  • Gynecology Oncology Associates Newport Beach Newport Beach, California, United States
View all 47 locations
View Trial Details
Completed

H.O.P.E: Helping Ovarian Cancer Patients Cope

NCT02090582

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +15 more
Locations
  • University of North Carolina Chapel Hill, North Carolina, United States
  • Duke University Medical Center Durham, North Carolina, United States
View Trial Details

Related conditions